Target LDL Levels Based on Cardiovascular Risk

Risk Categories and Corresponding LDL Targets

The European Society of Cardiology recommends LDL cholesterol targets of <1.4 mmol/L (<55 mg/dL) for very high-risk patients, <1.8 mmol/L (<70 mg/dL) for high-risk patients, <2.6 mmol/L (<100 mg/dL) for moderate-risk patients, and <3.0 mmol/L (<116 mg/dL) for low-risk patients, with a minimum 50% reduction from baseline for high and very high-risk categories 1, 2
Very high-risk patients, including those with established cardiovascular disease, diabetes with target organ damage, or severe chronic kidney disease, should aim for an LDL target of <1.4 mmol/L (<55 mg/dL) and ≥50% reduction from baseline 1, 2, 3, 4
High-risk patients, including those with markedly elevated single risk factors, diabetes without target organ damage, or moderate chronic kidney disease, should aim for an LDL target of <1.8 mmol/L (<70 mg/dL) and ≥50% reduction from baseline 1, 2, 3, 4
Moderate-risk patients, including young patients with diabetes and no additional risk factors, should aim for an LDL target of <2.6 mmol/L (<100 mg/dL) 1, 2, 4, 5
Low-risk patients, including those with a calculated 10-year risk <5%, should aim for an LDL target of <3.0 mmol/L (<116 mg/dL) 3, 5, 6

The American College of Cardiology/American Heart Association recommends using the Pooled Cohort Equations to estimate 10-year risk of ASCVD 5
The European Society of Cardiology recommends using the SCORE system to estimate 10-year risk of fatal cardiovascular disease 3
The Framingham Risk Score can be used to estimate 10-year risk of coronary heart disease events 6

The European Society of Cardiology recommends starting statin therapy immediately with lifestyle modifications for very high-risk and high-risk patients 1, 3
For moderate-risk patients, intensive lifestyle modifications should be started first, with statin therapy added if targets are not achieved after 3-6 months 4, 5
For low-risk patients, lifestyle modifications should be the primary focus, with statin therapy considered if LDL-C remains >190 mg/dL 7, 8
High-intensity statin therapy is recommended for very high-risk and high-risk patients, with expected LDL-C reduction ≥50% 1, 2
Moderate-intensity statin therapy is recommended for moderate-risk patients, with expected LDL-C reduction 30-49% 5

Every 1.0 mmol/L reduction in LDL-C is associated with 20-25% reduction in cardiovascular events 3
Patients with diabetes should be treated according to their risk category, with most falling into high or very high-risk groups 1, 2, 9
Benefits of LDL lowering extend to older persons, but comorbidities and drug interactions should be considered 7
Children with diabetes should aim for an LDL-C target of <100 mg/dL 9

Lipid levels should be assessed 4-12 weeks after initiating therapy and after dose adjustments 1, 3
Annual monitoring is generally sufficient once the target is reached 3
Adherence, side effects, and cardiovascular risk factors should be evaluated at each visit 1, 3